We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Duration of Behavioral Counseling Treatment Needed to Optimize Smoking Abstinence (EDC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2011 by Harvard University Faculty of Medicine.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01038414
First Posted: December 24, 2009
Last Update Posted: June 23, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by:
Harvard University Faculty of Medicine
  Purpose
The purpose of this study is to determine if extending the behavioral smoking-cessation treatment period to one year will significantly improve cessation outcomes among those planning a quit attempt.

Condition Intervention Phase
Tobacco Addiction Behavioral: Extended Duration Behavioral Smoking Cessation Counseling Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Duration of Behavioral Counseling Treatment Needed to Optimize Smoking Abstinence

Resource links provided by NLM:


Further study details as provided by Harvard University Faculty of Medicine:

Primary Outcome Measures:
  • Proportion of subjects abstinent by treatment group at 1 year post-cessation. [ Time Frame: One year ]

Secondary Outcome Measures:
  • Proportion of subjects abstinent by treatment group at 2 years post-cessation. [ Time Frame: Two years ]

Estimated Enrollment: 450
Study Start Date: February 2008
Estimated Study Completion Date: January 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Brief-Duration Counseling
3-Month Duration
Behavioral: Extended Duration Behavioral Smoking Cessation Counseling
Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
Other Name: Extended-Duration Behvioral Smoking-Cessation Counseling
Active Comparator: Moderate Duration Counseling
6-Month Duration
Behavioral: Extended Duration Behavioral Smoking Cessation Counseling
Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
Other Name: Extended-Duration Behvioral Smoking-Cessation Counseling
Active Comparator: Extended Duration Counseling
12-Month Duration
Behavioral: Extended Duration Behavioral Smoking Cessation Counseling
Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
Other Name: Extended-Duration Behvioral Smoking-Cessation Counseling

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Daily Cigarette Smokers

Exclusion Criteria:

  • Smokers with active atherosclerotic heart disease, severe cardiac arrhythmias, uncontrolled hypertension, severe peripheral vascular disease, pre-controlled diabetes mellitus, pregnancy, lactation or likely to become pregnant during the study period, and chronic dermatologic disease.
  • Smokers who meet DSM-IV lifetime criteria for conditions such as schizo-affective disorder and schizophrenia, bi-polar disorder, or who have had alcohol or drug dependence issues within the past year.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01038414


Locations
United States, Massachusetts
Harvard School of Dental Medicine Recruiting
Boston, Massachusetts, United States, 02115
Contact: Arthur J Garvey, PhD    617-523-8558    arthur_garvey@hms.harvard.edu   
Principal Investigator: Arthur J Garvey, Ph.D.         
Sponsors and Collaborators
Harvard University Faculty of Medicine
National Institute on Drug Abuse (NIDA)
  More Information

Responsible Party: Arthur J. Garvey, Ph.D., Harvard School of Dental Medicine
ClinicalTrials.gov Identifier: NCT01038414     History of Changes
Other Study ID Numbers: 5R01DA12165-8
5R01DA012165 ( U.S. NIH Grant/Contract )
First Submitted: December 22, 2009
First Posted: December 24, 2009
Last Update Posted: June 23, 2011
Last Verified: June 2011